TN2013000151A1 - Polypeptides derived from il-2 having agonist activity for the therapy of cancer and chronic infections - Google Patents

Polypeptides derived from il-2 having agonist activity for the therapy of cancer and chronic infections

Info

Publication number
TN2013000151A1
TN2013000151A1 TNP2013000151A TN2013000151A TN2013000151A1 TN 2013000151 A1 TN2013000151 A1 TN 2013000151A1 TN P2013000151 A TNP2013000151 A TN P2013000151A TN 2013000151 A TN2013000151 A TN 2013000151A TN 2013000151 A1 TN2013000151 A1 TN 2013000151A1
Authority
TN
Tunisia
Prior art keywords
polypeptides
cancer
therapy
relates
regulatory
Prior art date
Application number
TNP2013000151A
Other languages
French (fr)
Inventor
Monzon Kalet Leon
Portilla Tania Carmenate
Rodriguez Saumel Perez
Escalona Neris Michel Enamorado
Bienvenido Lage Davila Agustin
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CU2011/000007 external-priority patent/WO2012062228A2/en
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of TN2013000151A1 publication Critical patent/TN2013000151A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to polypeptides that have the same primary sequence as human IL-2, except that some amino acids have been mutated. The mutations introduced substantially reduce the capacity of these polypeptides for the in vitro and in vivo stimulation of regulatory T cells (T CD4+CD25+FoxP3+) and increase the efficacy of said polypeptides in the therapy of murine transplantable tumours. The invention also relates to the therapeutic uses of these variants, either alone or combined with vaccines, for the therapy of diseases, such as cancer or infections in which the activity of the regulatory T cells (Tregs) is relevant. The invention further relates to pharmaceutical compositions comprising the aforementioned polypeptides as an active principle. In addition, the invention relates to the therapeutic use of said polypeptides and pharmaceutical compositions, making use of their ability to modulate the immune system in relation to pathologies such as cancer and chronic infectious diseases.
TNP2013000151A 2011-11-10 2013-04-04 Polypeptides derived from il-2 having agonist activity for the therapy of cancer and chronic infections TN2013000151A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CU2011/000007 WO2012062228A2 (en) 2010-11-12 2011-11-10 Polypeptides derived from il-2 having agonist activity, for the therapy of cancer and chronic infections

Publications (1)

Publication Number Publication Date
TN2013000151A1 true TN2013000151A1 (en) 2014-11-10

Family

ID=54360593

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000151A TN2013000151A1 (en) 2011-11-10 2013-04-04 Polypeptides derived from il-2 having agonist activity for the therapy of cancer and chronic infections

Country Status (1)

Country Link
TN (1) TN2013000151A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022078185A1 (en) * 2020-10-18 2022-04-21 北京志道生物科技有限公司 Interleukin-2 mutant

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022078185A1 (en) * 2020-10-18 2022-04-21 北京志道生物科技有限公司 Interleukin-2 mutant

Similar Documents

Publication Publication Date Title
MX2013005250A (en) Polypeptides derived from il-2 having agonist activity, for the therapy of cancer and chronic infections.
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
MY162324A (en) Immunomodulatory polypeptides derived from il-2 and their use thereof in the therapeutic of cancer and chronic infections
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
NZ702801A (en) Treatment of sanfilippo syndrome type b
IN2012DN06720A (en)
PH12021551189A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
MY188139A (en) Sodium channel modulators for the treatment of pain
MX2012007806A (en) Pharmaceutical compositions for oral administration of insulin peptides.
NZ708016A (en) Lyophilized preparations of melphalan flufenamide
BR112014011981A8 (en) ORAL SOLID PHARMACEUTICAL FORMULATIONS, THEIR PREPARATION PROCESSES AND USES
MX2021010041A (en) Pharmaceutical compositions comprising akt protein kinase inhibitors.
IN2014DN03213A (en)
UY33219A (en) CYCLIC CETOENOLS FOR THERAPIES
UA114298C2 (en) Tork peptides and vaccines including the same
GEP20156332B (en) Pyrazoles as crth2 antagonists
WO2019098759A3 (en) Transformed human cell and use thereof
MX2017005163A (en) Onapristone extended-release compositions and methods.
MX368943B (en) Storage stable lyophilized tripeptide formulations.
TN2013000151A1 (en) Polypeptides derived from il-2 having agonist activity for the therapy of cancer and chronic infections
MX2015014905A (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS.
PH12015502420A1 (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
MX2019007906A (en) Vaccine composition comprising a mutation of human interleukin-15.
TH141466A (en) LL-2 derivative polypeptide with agonist activity for cancer therapy And chronic infections